ImmusanT

About:

ImmusanT is a biotechnology company developing diagnostics and therapeutics for the diagnosis and treatment of celiac disease.

Website: http://www.immusant.com

Twitter/X: ImmusanT

Top Investors: ARCH Venture Partners, JDRF T1D Fund, Vatera Healthcare Partners

Description:

ImmusanT is a biotechnology company that develops diagnostics and therapeutics for the diagnosis and treatment of celiac disease. The company focuses on restoring tolerance to gluten in celiac disease by harnessing new discoveries in immunology that improve diagnosis and treatment. It develops Nexvax2, a therapeutic vaccine for treating, preventing, and diagnosing celiac disease. The company also develops a functional T-cell test to diagnose and monitor the maintenance of immune tolerance with peptide based therapy. ImmusanT was incorporated in 2010 and is based in Cambridge, Massachusetts.

Total Funding Amount:

$72.8M

Estimated Revenue Range:

Less than $1M

Headquarters Location:

Cambridge, Massachusetts, United States

Founded Date:

2011-06-08

Contact Email:

info(AT)immusant.com

Founders:

Leslie Williams

Number of Employees:

1-10

Last Funding Date:

2018-09-11

IPO Status:

Private

Industries:

© 2025 bioDAO.ai